Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04400331 · ClinicalTrials.gov registry record · Phase 3
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
A Phase 3 study of Chorea, Huntington, sponsored by Neurocrine Biosciences.
- Active
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
- 20
- Study locations
NCT04400331: Active Phase 3 study of Chorea, Huntington, sponsored by Neurocrine Biosciences.
NCT04400331 is a Phase 3 study of Chorea, Huntington that is active but no longer recruiting, run by Neurocrine Biosciences. The registered enrollment target is 154 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04400331, a Phase 3 study of Chorea, Huntington, is active but no longer recruiting, sponsored by Neurocrine Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
Conditions Studied
Interventions
- DRUG Valbenazine
Study Locations (20)
Florida
- Neurocrine Clinical Site - Boca Raton
- Neurocrine Clinical Site - Gainesville
Illinois
- Neurocrine Clinical Site - Chicago
- Neurocrine Clinical Site - Chicago
Massachusetts
- Neurocrine Clinical Site - Boston
- Neurocrine Clinical Site - Charlestown
Alabama
- Neurocrine Clinical Site - Birmingham
Arkansas
- Neurocrine Clinical Site - Little Rock
California
- Neurocrine Clinical Site - La Jolla
Colorado
- Neurocrine Clinical Site - Aurora
District of Columbia
- Neurocrine Clinical Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
What the registry record for NCT04400331 still lists
NCT04400331 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Chorea, Huntington appearing as the primary indexed condition, and to 1 intervention - of which Valbenazine is the first listed.
NCT04400331 names 20 study sites across 17 states, led by Florida, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04400331 about?
NCT04400331 is a clinical study titled "Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease". This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
What is the current status of trial NCT04400331?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2020-09-18. Estimated completion is 2026-03.
What conditions does trial NCT04400331 study?
This clinical trial studies the following conditions: Chorea, Huntington.
What interventions are being tested in trial NCT04400331?
The interventions under investigation include: Valbenazine (DRUG).
Who is sponsoring clinical trial NCT04400331?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04400331 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chorea, Huntington
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04400331's enrollment target sits among peer trials
154 1510th of 2000 higher than 491 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI